Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP – Get Free Report) announced its quarterly earnings data on Friday. The company reported ($1.23) EPS for the quarter, beating the consensus estimate of ($2.01) by $0.78, Zacks reports.
Neuphoria Therapeutics Inc. – Common Stock Stock Performance
NEUP stock traded up $0.20 on Friday, hitting $4.80. The company had a trading volume of 49,914 shares, compared to its average volume of 1,079,359. Neuphoria Therapeutics Inc. – Common Stock has a 12-month low of $2.12 and a 12-month high of $15.96.
Analyst Ratings Changes
Separately, HC Wainwright increased their target price on Neuphoria Therapeutics Inc. – Common Stock from $8.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, February 4th.
Neuphoria Therapeutics Inc. – Common Stock Company Profile
Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Read More
- Five stocks we like better than Neuphoria Therapeutics Inc. – Common Stock
- What is a Death Cross in Stocks?
- NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide Investment
- Earnings Per Share Calculator: How to Calculate EPS
- Up 50% in January, Twilio’s Pullback is the Time to Buy
- Quiet Period Expirations Explained
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
Receive News & Ratings for Neuphoria Therapeutics Inc. - Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics Inc. - Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
